PML-RARA fusion oncoprotein

Class

Small molecule (oral arsenic trioxide formulation)

Pathway

Binds and induces degradation of the PML-RARA fusion protein, triggering differentiation and apoptosis of APL blasts

PML-RARA is a fusion oncoprotein created when a chromosomal rearrangement joins two separate genes—promyelocytic leukemia (PML) and the retinoic acid receptor alpha (RARA)—into a single abnormal protein. Normally, retinoic acid signaling through RARA drives immature myeloid cells to mature into functional white blood cells. The fusion protein disrupts this process by aberrantly recruiting repressive protein complexes to genes required for differentiation, effectively freezing cells at an early promyelocyte stage while also promoting their survival and proliferation. This is the defining molecular lesion of acute promyelocytic leukemia (APL), a distinct subtype of acute myeloid leukemia. Because the fusion protein exists only in leukemic cells and not in normal tissue, it represents a highly specific therapeutic target, offering a route to selective cell killing that spares healthy blood-forming cells. Agents that bind and degrade the fusion protein remove the block on differentiation, allowing malignant promyelocytes to mature and subsequently undergo programmed cell death. This mechanism underlies a broader principle in oncology: targeting the specific molecular lesion driving a cancer, rather than relying on generalized cytotoxic effects, can achieve disease control with a more favorable balance between efficacy and harm to normal cells.